CD8A and neoplasm: Our results show that treatment with Dox plus IL-12 increased the number of NKG2D-positive CD8+T cells in tumor-bearing mice (Figures 1 and 2) and promoted the localization of NKG2D-positive CD8+T cells in tumors (Figures 3, 4, 5).